ChemoCentryx (CCXI)

P/S ratio on November 25, 2022 (TTM) : 101

According to ChemoCentryx's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is N/A. At the end of 2022 the company had a P/S ratio of 47.5.

P/S ratio history for ChemoCentryx from 2012 to 2022

PS ratio at the end of each year

Year	P/S ratio	Change
2022	47.5	-40.54%
2021	79.9	20.11%
2020	66.6	0.44%
2019	66.3	414.1%
2018	12.9	266.45%
2017	3.52	-88.63%
2016	30.9
2015	N/A
2014	N/A	-100%
2013	41.0	-44.17%
2012	73.4

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Biogen BIIB	2.40	-97.62%	🇺🇸 USA
AbbVie ABBV	6.35	-93.68%	🇺🇸 USA
GSK plc GSK	2.30	-97.71%	🇬🇧 UK
Bristol-Myers Squibb BMY	2.34	-97.67%	🇺🇸 USA
Johnson & Johnson JNJ	5.72	-94.31%	🇺🇸 USA
Amgen AMGN	4.95	-95.08%	🇺🇸 USA
Pfizer PFE	2.32	-97.69%	🇺🇸 USA
Teva Pharmaceutical Industries TEVA	2.17	-97.84%	🇮🇱 Israel
Merck MRK	4.23	-95.79%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for ChemoCentryx (CCXI)

P/S ratio on November 25, 2022 (TTM) : 101